SG11201708151TA - Method of monomerisation of recombinant antibody molecules - Google Patents
Method of monomerisation of recombinant antibody moleculesInfo
- Publication number
- SG11201708151TA SG11201708151TA SG11201708151TA SG11201708151TA SG11201708151TA SG 11201708151T A SG11201708151T A SG 11201708151TA SG 11201708151T A SG11201708151T A SG 11201708151TA SG 11201708151T A SG11201708151T A SG 11201708151TA SG 11201708151T A SG11201708151T A SG 11201708151TA
- Authority
- SG
- Singapore
- Prior art keywords
- monomerisation
- antibody molecules
- recombinant antibody
- recombinant
- molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/123—Tripeptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1506870.3A GB201506870D0 (en) | 2015-04-22 | 2015-04-22 | Method |
PCT/EP2016/059051 WO2016170138A1 (en) | 2015-04-22 | 2016-04-22 | Method of monomerisation of recombinant antibody molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201708151TA true SG11201708151TA (en) | 2017-11-29 |
Family
ID=53299019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201708151TA SG11201708151TA (en) | 2015-04-22 | 2016-04-22 | Method of monomerisation of recombinant antibody molecules |
Country Status (17)
Country | Link |
---|---|
US (2) | US10828366B2 (en) |
EP (1) | EP3286204B1 (en) |
JP (1) | JP6898251B2 (en) |
KR (1) | KR20170138552A (en) |
CN (1) | CN108064230B (en) |
AU (1) | AU2016251620A1 (en) |
BR (1) | BR112017021812A2 (en) |
CA (1) | CA2981644C (en) |
CL (1) | CL2017002676A1 (en) |
CO (1) | CO2017010385A2 (en) |
EA (1) | EA201792329A1 (en) |
ES (1) | ES2846732T3 (en) |
GB (1) | GB201506870D0 (en) |
IL (1) | IL254765A0 (en) |
MX (1) | MX2017013376A (en) |
SG (1) | SG11201708151TA (en) |
WO (1) | WO2016170138A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201223276D0 (en) * | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
IL252712B2 (en) | 2014-12-22 | 2024-04-01 | UCB Biopharma SRL | Method of protein manufacture |
GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
AU2019356564A1 (en) * | 2018-10-11 | 2021-04-29 | Amgen Inc. | Downstream processing of bispecific antibody constructs |
WO2022122654A1 (en) * | 2020-12-07 | 2022-06-16 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
DK336987D0 (en) | 1987-07-01 | 1987-07-01 | Novo Industri As | immobilization |
US5453363A (en) | 1985-10-23 | 1995-09-26 | Boehringer Mannheim Gmbh | Process for the activation of t-PA or Ing after genetic expression in prokaryotes |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
CA1340288C (en) | 1988-09-02 | 1998-12-29 | Robert Charles Ladner | Generation and selection of novel binding proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
ATE356869T1 (en) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | FORMATION OF XENOGENE ANTIBODIES |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
ES2246502T3 (en) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
DE69129154T2 (en) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES |
ATE269401T1 (en) | 1991-04-10 | 2004-07-15 | Scripps Research Inst | LIBRARIES OF HETERODIMERIC RECEPTORS USING PHAGEMIDS |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
DE69233745D1 (en) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Preparation of Autoantibodies on Phage Surfaces Starting from Antibody Segment Libraries |
WO1993016185A2 (en) * | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
AU696293B2 (en) | 1993-12-08 | 1998-09-03 | Genzyme Corporation | Process for generating specific antibodies |
EP0744958B1 (en) | 1994-01-31 | 2003-06-25 | Trustees Of Boston University | Polyclonal antibody libraries |
FR2716640B1 (en) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Device for centering and blocking a workpiece with a view to running it in using an expansion lapper. |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
JP2978435B2 (en) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | Method for producing acryloxypropyl silane |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
JP4799736B2 (en) * | 1999-02-22 | 2011-10-26 | ジョージタウン・ユニバーシティ | Antibody fragment targeted immunoliposomes for systemic gene delivery |
WO2010036767A1 (en) * | 2008-09-26 | 2010-04-01 | Schering Corporation | High titer antibody production |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
ES2545745T3 (en) | 2002-05-02 | 2015-09-15 | Wyeth Holdings Llc | Transporter conjugates derived from caliqueamycin |
WO2003097669A2 (en) * | 2002-05-17 | 2003-11-27 | Københavns Universitet | Method for purifying denatured proteins having a desired disulfide bond configuration |
CA2507004A1 (en) | 2002-12-03 | 2004-06-17 | Celltech R & D Limited | Assay for identifying antibody producing cells |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
GB0315450D0 (en) * | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
SI1644412T2 (en) | 2003-07-01 | 2018-11-30 | Ucb Biopharma Sprl | Modified antibody fab fragments |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
CA2567520A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Maytansinoid-antibody conjugates |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
US20060051347A1 (en) | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
MX2007004437A (en) | 2004-10-22 | 2007-06-20 | Amgen Inc | Methods for refolding of recombinant antibodies. |
AU2006272714A1 (en) | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | Compositions and methods for protein deaggregation |
US20070191272A1 (en) | 2005-09-27 | 2007-08-16 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
EP2535350B1 (en) | 2007-09-26 | 2018-01-24 | UCB Biopharma SPRL | Dual specificity antibody fusions |
SG2013061528A (en) | 2008-08-14 | 2015-03-30 | Merck Sharp & Dohme | Methods for purifying antibodies using protein a affinity chromatography |
LT2334705T (en) | 2008-09-26 | 2017-03-27 | Ucb Biopharma Sprl | Biological products |
MX2011013417A (en) | 2009-06-25 | 2012-03-29 | Amgen Inc | Capture purification processes for proteins expressed in a non-mammalian system. |
US20120283415A1 (en) | 2009-09-10 | 2012-11-08 | Ucb Pharma S.A. | Multivalent Antibodies |
GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
GB0920127D0 (en) * | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
BR112012022518A2 (en) * | 2010-03-17 | 2020-10-13 | Biogenerix Gmbh | method for obtaining biologically active recombinant human g-csf |
GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
EP2550297B1 (en) | 2010-03-25 | 2019-01-23 | UCB Biopharma SPRL | Disulfide stabilized dvd-lg molecules |
US9193760B2 (en) * | 2010-09-20 | 2015-11-24 | Bio-Rad Laboratories, Inc. | Dissociation of product-complexed contaminants in chromatography |
US8759617B2 (en) * | 2010-09-21 | 2014-06-24 | National Institute Of Agrobiological Sciences | Method for extraction and purification of recombinant proteins from transgenic plants |
CA2847888A1 (en) * | 2011-09-09 | 2013-03-14 | Biomed Realty, L.P. | Methods and compositions for controlling assembly of viral proteins |
EA033766B1 (en) * | 2011-11-11 | 2019-11-22 | Ucb Biopharma Sprl | Albumin binding antibodies and binding fragments thereof |
UA112203C2 (en) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Fusion protein of a biospecific antibody that binds to human OX40 and serum human albumin |
US20160060291A1 (en) | 2012-03-30 | 2016-03-03 | Biogenomics Limited | Process for renaturation of polypeptides |
GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
DK3447069T3 (en) * | 2012-11-21 | 2020-11-16 | Janssen Biotech Inc | BISPECIFIC EGFR / C-MET ANTIBODIES |
EP3114223A1 (en) | 2014-03-07 | 2017-01-11 | Bionano Genomics, Inc. | Processing of polynucleotides |
GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
GB201506870D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
KR20190038896A (en) | 2016-08-12 | 2019-04-09 | 론자 리미티드 | Proteomic analysis of host cell proteins |
-
2015
- 2015-04-22 GB GBGB1506870.3A patent/GB201506870D0/en not_active Ceased
-
2016
- 2016-04-22 BR BR112017021812A patent/BR112017021812A2/en active Search and Examination
- 2016-04-22 KR KR1020177033853A patent/KR20170138552A/en unknown
- 2016-04-22 EP EP16719824.1A patent/EP3286204B1/en active Active
- 2016-04-22 AU AU2016251620A patent/AU2016251620A1/en not_active Abandoned
- 2016-04-22 WO PCT/EP2016/059051 patent/WO2016170138A1/en active Application Filing
- 2016-04-22 ES ES16719824T patent/ES2846732T3/en active Active
- 2016-04-22 MX MX2017013376A patent/MX2017013376A/en unknown
- 2016-04-22 JP JP2017555223A patent/JP6898251B2/en active Active
- 2016-04-22 CN CN201680022972.8A patent/CN108064230B/en active Active
- 2016-04-22 CA CA2981644A patent/CA2981644C/en active Active
- 2016-04-22 EA EA201792329A patent/EA201792329A1/en unknown
- 2016-04-22 US US15/566,307 patent/US10828366B2/en active Active
- 2016-04-22 SG SG11201708151TA patent/SG11201708151TA/en unknown
-
2017
- 2017-09-28 IL IL254765A patent/IL254765A0/en unknown
- 2017-10-11 CO CONC2017/0010385A patent/CO2017010385A2/en unknown
- 2017-10-20 CL CL2017002676A patent/CL2017002676A1/en unknown
-
2020
- 2020-10-23 US US17/078,127 patent/US11786593B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN108064230B (en) | 2021-04-06 |
ES2846732T3 (en) | 2021-07-29 |
EP3286204B1 (en) | 2020-11-18 |
JP6898251B2 (en) | 2021-07-07 |
US11786593B2 (en) | 2023-10-17 |
CA2981644A1 (en) | 2016-10-27 |
US20180117153A1 (en) | 2018-05-03 |
JP2018515449A (en) | 2018-06-14 |
EA201792329A1 (en) | 2018-02-28 |
IL254765A0 (en) | 2017-12-31 |
WO2016170138A1 (en) | 2016-10-27 |
US10828366B2 (en) | 2020-11-10 |
CN108064230A (en) | 2018-05-22 |
GB201506870D0 (en) | 2015-06-03 |
CA2981644C (en) | 2023-07-04 |
US20210069328A1 (en) | 2021-03-11 |
MX2017013376A (en) | 2017-12-07 |
CL2017002676A1 (en) | 2018-03-23 |
BR112017021812A2 (en) | 2018-07-10 |
KR20170138552A (en) | 2017-12-15 |
EP3286204A1 (en) | 2018-02-28 |
CO2017010385A2 (en) | 2018-03-20 |
AU2016251620A1 (en) | 2017-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285366A (en) | Multispecific antigen-binding proteins | |
ZA201907054B (en) | Anti-tau antibodies and methods of use | |
HK1254198A1 (en) | Optimized variants of anti-vegf antibodies | |
IL249955A0 (en) | Method of computational protein design | |
GB201601075D0 (en) | Antibodies molecules | |
IL254765A0 (en) | Method of monomerisation of recombinant antibody molecules | |
GB201522391D0 (en) | Antibody molecules | |
HK1251582A1 (en) | Humanized anti-tau(ps422) antibodies and methods of use | |
IL248697A0 (en) | Methods of purifying antibodies | |
GB201518792D0 (en) | Production of proteins | |
IL255094A0 (en) | Method for increasing the percentage of monomeric antibody fab-dsfv multimeric species | |
HUP1500363A2 (en) | Method for increasing the galactose content of recombinant proteins | |
GB201604627D0 (en) | Improved method of FT-IMS | |
LT3337820T (en) | An improved refolding process for antibody`s fragments | |
IL258981A (en) | Methods for producing proteins | |
SG11201800894SA (en) | Method for parallel quantification of protein variant | |
HK1255456A1 (en) | Expression of fc-containing proteins | |
IL252712A0 (en) | Method of protein manufacture | |
IL248694A0 (en) | Nanoencapsulation of antigen-binding molecules | |
GB201518675D0 (en) | Detection of structural forms of proteins | |
HK1255728A1 (en) | Treatment of asthma with anti-il-23a antibodies | |
IL256707B (en) | Method for production of recombinant proteins | |
IL256706B (en) | Method for production of recombinant proteins | |
GB201509048D0 (en) | Method of assembly | |
IL251740B (en) | A method of producing vials of recombinant protein |